Investment Summary |
|
|---|---|
| Date | 2013-07-10 |
| Target | Loxo Oncology |
| Sector | Life Science |
| Investor(s) | Aisling Capital |
| Deal Type | Venture |
SEARCH BY
| Category | Private Equity Firm |
|---|---|
| Founded | 2000 |
| PE ASSETS | 1.8B USD |
| Size | Large |
| Type | Sector Focused |
Aisling Capital is a private investment firm focused on opportunities in the healthcare and medical technology sectors. The Firm specifically looks to invest in companies developing and commercializing innovative healthcare products, services, and technologies. Aisling Capital looks to commit $20 to $50 million per investment and prefers to be the lead investor. Aisling will consider investing in both public and private companies. Aisling Capital raised its first fund in 2000. The Firm is based in New York City.
| DEAL STATS | # |
|---|---|
| Overall | 33 of 56 |
| Sector: Life Science M&A | 23 of 42 |
| Type: Venture M&A Deals | 20 of 29 |
| State: Connecticut M&A | 1 of 1 |
| Country: United States M&A | 32 of 52 |
| Year: 2013 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-06-17 |
Aragon Pharmaceuticals
San Diego, California, United States Aragon Pharmaceuticals is a privately held, small-molecule drug discovery company focused on developing breakthrough medicines for the treatment of hormonally-driven cancers. |
Sell | $1.0B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-07-24 |
Paratek Pharmaceuticals
King of Prussia, Pennsylvania, United States Paratek Pharmaceuticals is a bio-pharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek Pharmaceuticals was founded in 1996 and is based in King of Prussia, Pennsylvania. |
Sell | - |
